UK-based BenevolentAI has dosed the first patient in its first-in-human clinical trial of its novel multi-target drug, BEN-2293, for treating atopic dermatitis (AD).
Designed and developed using BenevolentAI’s scientific and technical expertise, BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery.
BenevolentAI has dosed the first patient in its clinical trial of its novel multi-target drug, BEN-2293, for treating atopic dermatitis (AD).